Deutsch names Dowshen to head Zelnorm and Diovan business

Share this article:
Deutsch named Matt Dowshen to head the firm's business on Novartis' Zelnorm and Diovan. Dowshen, who joined from JWT New York, where he was senior partner/director-in-charge and co-leader of the DeBeers account, becomes SVP/group account director at Deutsch New York. In addition to the Novartis business, he will head the firm's IKEA account, reporting to Deutsch New York president Val DiFebo.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.